Risk assessment in hypertrophic cardiomyopathy: contemporary guidelines hampered by insufficient evidence.
作者信息
McKeown Pascal P, Muir Alison Rachel
出版信息
Heart. 2013 Apr;99(8):511-3. doi: 10.1136/heartjnl-2012-303363. Epub 2013 Feb 2.
Abstract
摘要
相似文献
1
Risk assessment in hypertrophic cardiomyopathy: contemporary guidelines hampered by insufficient evidence.
Heart. 2013 Apr;99(8):511-3. doi: 10.1136/heartjnl-2012-303363. Epub 2013 Feb 2.
2
A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy.
Heart. 2013 Apr;99(8):534-41. doi: 10.1136/heartjnl-2012-303271. Epub 2013 Jan 22.
3
Certification of competitive sports participation of a professional soccer player with hypertrophic cardiomyopathy and implanted ICD.
Clin Res Cardiol. 2016 Aug;105(8):710-713. doi: 10.1007/s00392-016-0978-9. Epub 2016 Mar 22.
4
Between an ICD and a hard place.
J Cardiovasc Electrophysiol. 2011 Oct;22(10):1120-2. doi: 10.1111/j.1540-8167.2011.02092.x. Epub 2011 Jun 2.
5
Athletes with implantable cardioverter defibrillators: can they return to competitive sports?
Heart. 2016 Jan;102(2):93-4. doi: 10.1136/heartjnl-2015-309152rep.
6
Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
Circ Arrhythm Electrophysiol. 2018 Apr;11(4):e005820. doi: 10.1161/CIRCEP.117.005820.
7
Extensive myocardial fibrosis in a patient with hypertrophic cardiomyopathy and ventricular tachycardia without traditional high-risk features.
Circ Cardiovasc Imaging. 2009 Jul;2(4):349-50. doi: 10.1161/CIRCIMAGING.108.824839.
8
ESC sudden-death risk model in hypertrophic cardiomyopathy: Incremental value of quantitative contrast-enhanced CMR in intermediate-risk patients.
Clin Cardiol. 2017 Oct;40(10):853-860. doi: 10.1002/clc.22735. Epub 2017 Jun 14.
9
Can sudden cardiac death be prevented?
Cardiovasc Pathol. 2010 Nov-Dec;19(6):329-35. doi: 10.1016/j.carpath.2010.03.002. Epub 2010 Apr 8.
10
Risk stratification and prevention of sudden death in hypertrophic cardiomyopathy.
Cardiol Rev. 2002 May-Jun;10(3):173-81. doi: 10.1097/00045415-200205000-00006.
引用本文的文献
1
Recommendations of the current guidelines for implantable cardioverter-defibrillator implantation in patients with hypertrophic cardiomyopathy: Debate still exists.
J Interv Card Electrophysiol. 2021 Jan;60(1):1-7. doi: 10.1007/s10840-020-00837-4. Epub 2020 Jul 25.
2
Predictors of risk for sudden death in childhood hypertrophic cardiomyopathy: the importance of the ECG risk score.
Open Heart. 2017 Oct 21;4(2):e000658. doi: 10.1136/openhrt-2017-000658. eCollection 2017.
3
Arrhythmias in structural heart disease.
Curr Cardiol Rep. 2014 Aug;16(8):510. doi: 10.1007/s11886-014-0510-7.
本文引用的文献
1
A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy.
Heart. 2013 Apr;99(8):534-41. doi: 10.1136/heartjnl-2012-303271. Epub 2013 Jan 22.
2
Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis.
Circ Heart Fail. 2012 Sep 1;5(5):552-9. doi: 10.1161/CIRCHEARTFAILURE.112.969626. Epub 2012 Jul 20.
3
Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy.
JACC Cardiovasc Imaging. 2012 Apr;5(4):370-7. doi: 10.1016/j.jcmg.2011.11.021.
4
Subcutaneous chronic implantable defibrillation systems in humans.
J Interv Card Electrophysiol. 2012 Sep;34(3):325-32. doi: 10.1007/s10840-012-9665-6. Epub 2012 Mar 17.
5
Long-term outcomes in hypertrophic cardiomyopathy caused by mutations in the cardiac troponin T gene.
Circ Cardiovasc Genet. 2012 Feb 1;5(1):10-7. doi: 10.1161/CIRCGENETICS.111.959973. Epub 2011 Dec 5.
6
Prognostic importance of late gadolinium enhancement cardiovascular magnetic resonance in cardiomyopathy.
Heart. 2012 Mar;98(6):438-42. doi: 10.1136/heartjnl-2011-300814. Epub 2011 Nov 29.
7
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
Circulation. 2011 Dec 13;124(24):2761-96. doi: 10.1161/CIR.0b013e318223e230. Epub 2011 Nov 8.
8
Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy.
J Am Coll Cardiol. 2010 Sep 7;56(11):867-74. doi: 10.1016/j.jacc.2010.05.010. Epub 2010 Jun 25.
9
Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy.
J Am Coll Cardiol. 2010 Sep 7;56(11):875-87. doi: 10.1016/j.jacc.2010.05.007. Epub 2010 Jun 25.
10
Heart Rhythm UK position statement on clinical indications for implantable cardioverter defibrillators in adult patients with familial sudden cardiac death syndromes.
Europace. 2010 Aug;12(8):1156-75. doi: 10.1093/europace/euq261.
Zotero 插件